



PRODUCT LEAFLET FOR DOCTORS AND SURGERIES

To obtain CVTherapy, please contact CV Pharma on Tel: +44 (0) 7778 213337 or email: info@cvpharma.co.uk.

Please read this leaflet carefully

CVTherapy can only be prescribed for an individual by a Doctor and should not be passed on to others.

Presentation.

CVTherapy is supplied in blister packs in cardboard cartons. CVTherapy is a combination product consisting of 30 sodium salicylate 175mg tablets and 30 Essential Minerals and Vitamin C capsules (each capsule contains copper gluconate 10mg, manganese gluconate 10mg, and ascorbic acid (Vitamin C) 200mg). The individual constituents of CVTherapy are well characterised and used in other human medicines or supplements. All constituents are of pharmacopoeial specification.

What you should know about CVTherapy.

CVTherapy is a palliative treatment for cancer that is formulated to treat cancer which has been created by a deficiency of certain naturally occurring substances in the body. By replacing these substances, CVTherapy may bring about an improvement in the quality of life and potentially prevent the reoccurrence of tumours, and has no known serious or severe adverse side effects.

CVTherapy is patented as CV247 by Ivy Medical Chemicals Development Limited under Patent Number: GB2374008B

Benefits of CVTherapy.

- Strengthens the immune system which provides improved Quality of Life
- Forms part of the body's anti-oxidant defences
- May prevent the reoccurrence of tumours
- May aid recovery from surgery, chemotherapy or radiotherapy
- May be taken adjunctively with chemotherapy and radiotherapy

Before you use CVTherapy.

CVTherapy has been available for a significant number of years, and has proved to have minimal adverse side effects. However like all medicines, CVTherapy could potentially have minor side effects. Experiences from studies have demonstrated that adverse side effects are occasionally reported, predominantly relating to mild gastro-intestinal events such as gastric irritation, abdominal pain and bloating. No serious or severe reactions have ever been reported.

CVTherapy should **not** be prescribed if the patient may be allergic to any of the ingredients, or suffer from hepatobiliary disease and should **not** be prescribed to pregnant patients. Salicylates should only be co-administered with anti-coagulant drugs with caution.

CVTherapy Studies and Clinical Trials.

CVTherapy has been the subject of a number of pre-clinical studies undertaken to ascertain the anti-tumour properties of CVTherapy:

- A study in mice undertaken by Prof P Beverley at the Middlesex Hospital demonstrated a measurable reduction in the rate of tumour growth
- A study undertaken in mice by Biodynamics Ltd, which demonstrated tumour reduction was more apparent following treatment using CVTherapy rather than alternative substances.
- A chronic toxicology study was undertaken at Huntingdon Life Sciences, providing evidence that CVTherapy in dogs has a very low side effect profile, with no reports of either severe or serious adverse effects attributable to the drug.
- A study undertaken by Prof R Thomas at Addenbrooke's and Bedford Hospital evaluated the tumour static properties of CVTherapy, which wholly supported the clinical benefit in some types of cancer.
- A second study by Prof R Thomas, which resulted in a significant percentage of prostate cancer patients, who were recruited into the study, being stabilised following the treatment.

- A study undertaken by Dr Ros Taylor of the St Francis Hospice in Berkhamstead in order to ascertain how CVTherapy influenced quality of life found positive results in some patients with late stage cancers.
- A retrospective assessment conducted by Dr Ros Taylor over 5 years demonstrated significant symptom improvement or disease stabilisation in many patients.
- A preliminary viability investigation study undertaken by RGCC Limited (Research Genetic Cancer Centre) found that, after CVTherapy was added to a range of human cancer cell lines, it had a direct anti-cancer activity particularly in breast and colon cancers.
- A study in rats undertaken at Semmelweiss University in Budapest found that CVTherapy reduced the oxidative effects and reversed the cisplatin induced renal damage.

Dosage and administration.

CVTherapy should only be taken as prescribed. The dose prescribed will depend upon the patient's weight. CVTherapy should be taken orally with water.

The usual dose for adults and adolescents (13 years or more) is:

Bodyweight	CVTherapy daily dosage
Under 50 Kg	Two capsules and two tablets a day
50 - 75 Kg	Four capsules and four tablets a day
75 Kg and above	Six capsules and six tablets a day

Pharmaceutical precautions.

Keep CVTherapy out of reach and sight of children. Do not take CVTherapy after the expiry date, which is stated on the 2 packs. The expiry date refers to the last day of that month. Do not store above 25°C and store in the original package to protect the tablets & capsules from light.

How to obtain CVTherapy.

CVTherapy is only available as a "special" with a prescription from a doctor or pharmacy, please contact CV Pharma on Tel: +44 (0) 7778 213337 or email: info@cvpharma.co.uk.

CVTherapy – Contents.

One Unit comprises 30 tablets of Sodium Salicylate (175mg) and 30 capsules of Essential Minerals and Vitamin C.

Further Information & Enquiries

Further information is available on our website www.cv-pharma.com, username: cvpharma247 and password: cvpharma247

For general enquiries please contact CV Pharma on
Tel: +44 (0) 7778 213337
or email: info@cvpharma.co.uk